NCT06435910View on ClinicalTrials.gov

Engineered Dendritic Cell Vaccines for Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 11, 2024

Primary Completion Date

July 11, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple Myeloma or Plasmacytoma
Interventions
BIOLOGICAL

DC vaccines

Antigen-presenting and immune modifying DCvacs to treat MM

Trial Locations (2)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

690105

RECRUITING

The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok

All Listed Sponsors
collaborator

The No.2 Clinical Hospital of the Ministry of Health

UNKNOWN

lead

Shenzhen Geno-Immune Medical Institute

OTHER